Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265230 | 0.83 | HDAC3 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2152494 | 0.81 | KDM4E (0.35) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL363977 | 0.78 | CYP2D6 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL29134032 | 0.78 | CYP2D6 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL362095 | 0.78 | HDAC3 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2152321 | 0.77 | CYP2D6 (0.33) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2152110 | 0.76 | CYP2D6 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL222074 | 0.73 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL659374 | 0.73 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2151168 | 0.73 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-2340021-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | CYP2D6 954/4885HDAC3 100/4885HDAC1 57/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | CYP2D6 954/4885HDAC3 100/4885HDAC1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.